I am a faculty member (Professor) in the Departments of Medical Physics and Radiology, Director of Quantitative Imaging, Deputy Chief for the Service of Predictive Informatics, and Vice Chairman of Radiology-Medical Physics Outreach at Memorial Sloan Kettering Cancer Center (MSK). I am the previous Chairman of the Executive Committee and consolidated Working Group for NCI/Quantitative Imaging Network (QIN), a member of the Quantitative MR study group/International Society of Magnetic Resonance in Medicine (ISMRM), and a member of Computer Aided Image Analysis Subcommittee (CADSC)/ American Association of Physicists in Medicine (AAPM). I was named a Fellow of ISMRM in 2019. I am harmonizing my quantitative imaging (QI) and artificial intelligence (AI) efforts with external agencies, including the NCI/QIN, ISMRM/QMR, and AAPM/CADSC.

My clinical responsibility at MSK includes the development of quantitative imaging biomarkers (QIBs) using multimodality imaging for the clinical care of patients with cancer, working across departments in the era of AI to enrich clinical imaging. This involves creating an infrastructure that provides tools and expertise to standardize imaging protocols and metrics, implementing novel imaging methods, and fostering an environment for mentoring younger faculty and postdoctoral fellows in quantitative imaging. My group’s research focuses on developing and implementing advanced quantitative imaging biomarkers derived from MR imaging physics techniques, including diffusion-weighted MRI (DW-MRI), dynamic contrast-enhanced MRI (DCE-MRI), MR fingerprinting (MRF), and MR spectroscopy (MRS) for clinical application in cancer.

I established the head and neck (HN) cancer MR imaging research program in 2001. Over the years, I have extended my expertise in QI/AI to other organs, including the thyroid, brain, prostate, bladder, and pancreas. I developed an innovative program in multimodality imaging for oncology applications. My group has developed and identified quantitative imaging biomarkers for clinical endpoints, such as early assessment of treatment response. We lead the field by testing novel MRI acquisition prototypes, designing novel phantoms, and developing multi-parametric MRI analysis software packages.